Alzheimer's Disease: Biomarker and Treatment Revolution

Rapid advances in anti-amyloid therapies (donanemab, lecanemab, PMN310), tau-targeting ASOs (diranersen), blood-based biomarkers (pTau217, 34-circRNA), and non-invasive GENUS therapy. New oral oligomer inhibitor valiltramiprosate shows promise in APOE4/4. Global access expanding with India launch and Australia blood test implementation. Personalized DMT selection based on frailty and co-pathology emerging.